9th Sep 2015 05:38
LONDON (Alliance News) - GlaxoSmithKline PLC and partner Theravance Inc late on Tuesday announced the initial results from the Study to Understand Mortality and MorbidITy, or SUMMIT, trials conducted on the Relvar/Breo Ellipta drugs for the treatment of chronic obstructive pulmonary disease (COPD).
The FTSE 100 drugmaker said the risk of dying taking the drug dose was 12.2% lower than on placebo over the study period, which is not statistically significant and therefore meant the drug did not meet its primary endpoint.
In addition, the treatment missed its two secondary endpoint goals of reducing the rate of lung function decline or the risk of experiencing an on-treatment cardiovascular event, such as a stroke, angina or heart attack.
The study also examined a number of other COPD endpoints, including assessing the quality of the drug relative to placebos. Again, Glaxo said that while the drugs demonstrated an improvement compared to placebos, no statistical significance can be inferred.
"SUMMIT is an important study as this is the first time that survival has been studied in this under-researched co-morbid patient population. While we didn?t achieve statistical significance on the primary endpoint, we believe the full data set will be beneficial and informative to the respiratory and cardiovascular scientific community," said Eric Dube, the senior vice-president and head of the global respiratory franchise at Glaxo.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Glaxosmithkline